H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products